Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out what effects of high heated humidity has on you and your mucositis.


Clinical Trial Description

This is a open label, case-control randomized, phase II clinical trial comparing the use of High Heated Humidity (H3) delivered using the Airvo 2 device to standard of care in Hematologic cancer recipients of autologous stem cell transplant (including Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma). Mucositis and aerodigestive tract complications are common across most types of cytotoxic chemotherapies. These complications are both more frequent and severe in recipients of high dose chemotherapy (HDT) and autologous stem cell transplant (ASCT). By extending the use of H3 to include the HDT/ASCT population, there is the possibility to decrease or minimize the complications associated with the current standard treatment process. Shorter, less complicated hospital stays could results for those whose course would otherwise end up being longer due to complications/set- backs. The length of time to use the device per day is a minimum of 4 hours/day up to approximately 14 days while being an inpatient. Treatment beyond 14 days is exceptional and will be done only in those individuals who continue to have mucositis beyond 14 days. In this case, patients may receive treatment up to 30 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05358262
Study type Interventional
Source AHS Cancer Control Alberta
Contact Lisa Lem
Phone 780-432-8580
Email Lisa.Lem@albertahealthservices.ca
Status Not yet recruiting
Phase Phase 2
Start date July 2024
Completion date September 2025

See also
  Status Clinical Trial Phase
Approved for marketing NCT00291811 - Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization N/A
Completed NCT01296256 - Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). Phase 2
Recruiting NCT04653246 - Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM Phase 2
Active, not recruiting NCT02181413 - A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant Phase 3
Recruiting NCT04783038 - Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients N/A
Not yet recruiting NCT06377540 - MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Phase 2